Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

BioXcellence

EU flag

EC approves Biocon’s Stelara biosimilar Yesintek for inflammatory diseases

The drug has been approved to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease

- PMLiVE

Boehringer’s nerandomilast shows promise in phase 3 pulmonary fibrosis study

The company said it will now be submitting a new drug application for the candidate in this indication

- PMLiVE

Boehringer gains access to Synaffix’s ADC technology through $1.3bn licensing deal

The Lonza company will provide access to its ADC technologies for an undisclosed number of targets

EU flag

EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases

The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications

- PMLiVE

Boehringer Ingelheim’s Spevigo recommended by CHMP for generalised pustular psoriasis

The chronic neutrophilic inflammatory disease can lead to severe complications, including multisystem organ failure

- PMLiVE

Boehringer Ingelheim expands immuno-oncology pipeline with $1.3bn Nerio acquisition

The deal gives the company access to a preclinical immune checkpoint inhibitor programme

- PMLiVE

Boehringer Ingelheim’s Metalyse recommended by NICE to treat stroke in adults

Ischaemic stroke is responsible for around 85% of all stroke cases in the UK

- PMLiVE

Boehringer Ingelheim and Brainomix enter fibrosing lung disease partnership

Pulmonary fibrosis, a chronic lung condition, affects up to 20 out of every 100,000 people worldwide

- PMLiVE

Boehringer Ingelheim and 3T announce second cancer immunotherapy partnership

The collaboration brings the potential milestone payments of the agreements to $538.5m

- PMLiVE

Boehringer Ingelheim and Ribo announce liver disease partnership worth over $2bn

More than 440 million people worldwide are estimated to live with the inflammatory liver disease NASH

- PMLiVE

Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership

The collaboration will see Boehringer use an IBM-developed AI model to boost its drug discovery efforts

- PMLiVE

Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m

The acquisition marks a significant boost to Boehringer’s immuno-oncology portfolio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links